Wegener's granulomatosis: Patient-reported effects of disease on health, function, and income

Gary S. Hoffman, Yoel Drucker, Mary Frances Cotch, Geri A. Locker, Kirk Easley, Chian K Kwoh

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Objective. To evaluate the patient-perceived effects of Wegener's granulomatosis (WG) on health, function, income, and interpersonal relationships. Methods. A self-administered questionnaire, originally designed by the authors and subsequently revised with the aid of a patient focus group, was completed by 60 patients with well-defined features of WG. Patients had WG for a median period of 5 years. Results. Patients with chronic WG experienced substantial medical and functional morbidity and incurred significant socioeconomic losses. A prolonged delay in diagnosis (mean 16.8 months) and the need for multiple consultations prior to initiation of therapy may have contributed to medical morbidity. Although 73% of patients perceived their disease to be in remission following therapy, 78% of these patients required continuing immunosuppressive treatment many years after diagnosis. Eighty percent of patients reported that their normal activities of daily living were compromised. Half of those who were employed prior to diagnosis were required to modify their job or accept total disability (31%). A 26% (median) reduction in income within 1 year after diagnosis was reported. The effects of the disease on interpersonal relationships with a patient's spouse, family, and friends varied considerably. Conclusion. Advances in medical care have, for most patients, transformed WG from being a disease with a high potential for short-term mortality to being a chronic illness. This is the first study that has evaluated patients' assessments of the medical, socioeconomic, and quality of life effects of WG and its treatment. The effects of mortality, disability, and outpatient medical expenses indicate that the financial impact alone substantially exceeds prior estimates of $30 million per year in charges for hospitalizations in the US.

Original languageEnglish (US)
Pages (from-to)2257-2262
Number of pages6
JournalArthritis and Rheumatism
Volume41
Issue number12
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Granulomatosis with Polyangiitis
Health
Morbidity
Mortality
Therapeutics
Immunosuppressive Agents
Activities of Daily Living
Focus Groups
Spouses
Hospitalization
Chronic Disease
Outpatients
Referral and Consultation
Quality of Life

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Wegener's granulomatosis : Patient-reported effects of disease on health, function, and income. / Hoffman, Gary S.; Drucker, Yoel; Cotch, Mary Frances; Locker, Geri A.; Easley, Kirk; Kwoh, Chian K.

In: Arthritis and Rheumatism, Vol. 41, No. 12, 1998, p. 2257-2262.

Research output: Contribution to journalArticle

Hoffman, Gary S. ; Drucker, Yoel ; Cotch, Mary Frances ; Locker, Geri A. ; Easley, Kirk ; Kwoh, Chian K. / Wegener's granulomatosis : Patient-reported effects of disease on health, function, and income. In: Arthritis and Rheumatism. 1998 ; Vol. 41, No. 12. pp. 2257-2262.
@article{b575dd06a268493996f83a3b9e0bcbb5,
title = "Wegener's granulomatosis: Patient-reported effects of disease on health, function, and income",
abstract = "Objective. To evaluate the patient-perceived effects of Wegener's granulomatosis (WG) on health, function, income, and interpersonal relationships. Methods. A self-administered questionnaire, originally designed by the authors and subsequently revised with the aid of a patient focus group, was completed by 60 patients with well-defined features of WG. Patients had WG for a median period of 5 years. Results. Patients with chronic WG experienced substantial medical and functional morbidity and incurred significant socioeconomic losses. A prolonged delay in diagnosis (mean 16.8 months) and the need for multiple consultations prior to initiation of therapy may have contributed to medical morbidity. Although 73{\%} of patients perceived their disease to be in remission following therapy, 78{\%} of these patients required continuing immunosuppressive treatment many years after diagnosis. Eighty percent of patients reported that their normal activities of daily living were compromised. Half of those who were employed prior to diagnosis were required to modify their job or accept total disability (31{\%}). A 26{\%} (median) reduction in income within 1 year after diagnosis was reported. The effects of the disease on interpersonal relationships with a patient's spouse, family, and friends varied considerably. Conclusion. Advances in medical care have, for most patients, transformed WG from being a disease with a high potential for short-term mortality to being a chronic illness. This is the first study that has evaluated patients' assessments of the medical, socioeconomic, and quality of life effects of WG and its treatment. The effects of mortality, disability, and outpatient medical expenses indicate that the financial impact alone substantially exceeds prior estimates of $30 million per year in charges for hospitalizations in the US.",
author = "Hoffman, {Gary S.} and Yoel Drucker and Cotch, {Mary Frances} and Locker, {Geri A.} and Kirk Easley and Kwoh, {Chian K}",
year = "1998",
doi = "10.1002/1529-0131(199812)41:12<2257::AID-ART22>3.0.CO;2-K",
language = "English (US)",
volume = "41",
pages = "2257--2262",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "12",

}

TY - JOUR

T1 - Wegener's granulomatosis

T2 - Patient-reported effects of disease on health, function, and income

AU - Hoffman, Gary S.

AU - Drucker, Yoel

AU - Cotch, Mary Frances

AU - Locker, Geri A.

AU - Easley, Kirk

AU - Kwoh, Chian K

PY - 1998

Y1 - 1998

N2 - Objective. To evaluate the patient-perceived effects of Wegener's granulomatosis (WG) on health, function, income, and interpersonal relationships. Methods. A self-administered questionnaire, originally designed by the authors and subsequently revised with the aid of a patient focus group, was completed by 60 patients with well-defined features of WG. Patients had WG for a median period of 5 years. Results. Patients with chronic WG experienced substantial medical and functional morbidity and incurred significant socioeconomic losses. A prolonged delay in diagnosis (mean 16.8 months) and the need for multiple consultations prior to initiation of therapy may have contributed to medical morbidity. Although 73% of patients perceived their disease to be in remission following therapy, 78% of these patients required continuing immunosuppressive treatment many years after diagnosis. Eighty percent of patients reported that their normal activities of daily living were compromised. Half of those who were employed prior to diagnosis were required to modify their job or accept total disability (31%). A 26% (median) reduction in income within 1 year after diagnosis was reported. The effects of the disease on interpersonal relationships with a patient's spouse, family, and friends varied considerably. Conclusion. Advances in medical care have, for most patients, transformed WG from being a disease with a high potential for short-term mortality to being a chronic illness. This is the first study that has evaluated patients' assessments of the medical, socioeconomic, and quality of life effects of WG and its treatment. The effects of mortality, disability, and outpatient medical expenses indicate that the financial impact alone substantially exceeds prior estimates of $30 million per year in charges for hospitalizations in the US.

AB - Objective. To evaluate the patient-perceived effects of Wegener's granulomatosis (WG) on health, function, income, and interpersonal relationships. Methods. A self-administered questionnaire, originally designed by the authors and subsequently revised with the aid of a patient focus group, was completed by 60 patients with well-defined features of WG. Patients had WG for a median period of 5 years. Results. Patients with chronic WG experienced substantial medical and functional morbidity and incurred significant socioeconomic losses. A prolonged delay in diagnosis (mean 16.8 months) and the need for multiple consultations prior to initiation of therapy may have contributed to medical morbidity. Although 73% of patients perceived their disease to be in remission following therapy, 78% of these patients required continuing immunosuppressive treatment many years after diagnosis. Eighty percent of patients reported that their normal activities of daily living were compromised. Half of those who were employed prior to diagnosis were required to modify their job or accept total disability (31%). A 26% (median) reduction in income within 1 year after diagnosis was reported. The effects of the disease on interpersonal relationships with a patient's spouse, family, and friends varied considerably. Conclusion. Advances in medical care have, for most patients, transformed WG from being a disease with a high potential for short-term mortality to being a chronic illness. This is the first study that has evaluated patients' assessments of the medical, socioeconomic, and quality of life effects of WG and its treatment. The effects of mortality, disability, and outpatient medical expenses indicate that the financial impact alone substantially exceeds prior estimates of $30 million per year in charges for hospitalizations in the US.

UR - http://www.scopus.com/inward/record.url?scp=0032417031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032417031&partnerID=8YFLogxK

U2 - 10.1002/1529-0131(199812)41:12<2257::AID-ART22>3.0.CO;2-K

DO - 10.1002/1529-0131(199812)41:12<2257::AID-ART22>3.0.CO;2-K

M3 - Article

C2 - 9870883

AN - SCOPUS:0032417031

VL - 41

SP - 2257

EP - 2262

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 12

ER -